Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1626 1628 1629 1642
This examiner grants 52% of resolved cases
Brandon J Fetterolf is an examiner in Tech Center 1600 and Art Unit 1622, with 221 resolved cases. His allowance rate is 52.0 percent. This rate shows a balanced outcome for applicants, with roughly half of the cases resulting in an allowance. The 52.0 percent allowance rate suggests that success depends heavily on the technical merits and the quality of the prosecution strategy.
The interview lift is 17.4 percent. This positive lift suggests that engaging in an interview can meaningfully improve the chances of an application being allowed. For the 221 resolved cases, direct communication has proven to be a helpful strategy for clarifying issues and reaching agreement. Practitioners should consider the 17.4 percent lift as a valuable tool for advancing prosecution.
The median days to allowance is 1303. This is a relatively long duration, indicating that the path to a patent grant often involves multiple rounds of prosecution. Applicants should be prepared for a lengthy process, while using the 17.4 percent interview lift to navigate the 52.0 percent allowance rate environment. The 1303-day median is a key factor for long-term planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18033724 | COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | Non-Final OA | MERCK PATENT GMBH |
| 18716645 | METHOD FOR PRODUCING ISOXAZOLINECARBOXYLIC ACID DERIVATIVES | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 18010695 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 17912272 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | Final Rejection | THE GENERAL HOSPITAL CORPORATION |
| 18758879 | PROCESSES FOR MAKING IRAK4 INHIBITORS | Final Rejection | Gilead Sciences, Inc. |
| 18346745 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Final Rejection | Gilead Sciences, Inc. |
| 18729949 | SPIROCYCLIC PIPERIDINYL DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Non-Final OA | Novartis AG |
| 18030390 | NOVEL REDOX-BASED THERAPEUTIC APPROACH FOR TREATMENT OF CANCER | Final Rejection | THE PENN STATE RESEARCH FOUNDATION |
| 18178192 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18440036 | TRIGONELLINE MITIGATES CARDIOMYOPATHY CAUSED BY SARS-COV-2 SPIKE PROTEIN UNDER OBESITY | Final Rejection | University of South Carolina |
| 18035346 | USE OF DIHYDROMYRICETIN AS EPIGENETIC ACTIVE INGREDIENT FOR COSMETIC OR DERMATOLOGICAL SKIN CARE | Non-Final OA | BEIERSDORF AG |
| 18694614 | CANNABINOID-LIPID CONJUGATES, METHODS FOR PRODUCING THE SAME AND USES THEREOF | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18853504 | COMBINATION THERAPY FOR TREATING CANCER | Non-Final OA | AstraZeneca AB |
| 18564778 | METHODS OF TREATING BREAST CANCER | Non-Final OA | ASTRAZENECA AB |
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | Non-Final OA | TAIHO PHARMACEUTICAL CO., LTD. |
| 18253521 | Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof | Non-Final OA | Taiho Pharmaceutical Co., Ltd. |
| 18042103 | ORGANIC COMPOUNDS | Non-Final OA | INTRA-CELLULAR THERAPIES, INC. |
| 18568738 | COMPOUNDS THAT BIND NON-CANONICAL G-QUADRUPLEX STRUCTURES AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | The U.S.A., as Represented by the Secretary, Department of Health and Human Services |
| 17922890 | DOSING METHODS FOR TREATMENT OF CARDIOVASCULAR CONDITIONS | Non-Final OA | IMBRIA PHARMACEUTICALS, INC. |
| 17792042 | COMPOSITIONS AND METHODS | Non-Final OA | MONASH UNIVERSITY |
| 17912645 | IMIDAZOLYL THIOPEHENE SULFONYL CARBAMATES FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | Final Rejection | Vicore Pharma AB |
| 18372282 | SYNTHESIS OF A TETRAZOLE DERIVATIVE | Non-Final OA | Primodia Chemicals and Pharmaceuticals Private Limited |
| 18035011 | METHODS OF TREATING CORONAVIRUS DISEASE AND COMPOUNDS FOR SAME | Non-Final OA | Michal BRYLINSKI |
| 17999434 | Compositions and Methods for Treating Morphine, Heroin, and Alcohol Dependence | Non-Final OA | Babak Behnam |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy